4-[(5E)-5-(1H-indol-3-ylmethylidene)-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]butanoic acid

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 4-[(5E)-5-(1H-indol-3-ylmethylidene)-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]butanoic acid
• 化学式: C₁₆H₁₄N₂O₃S₂
• 分子量: 346.4
• InChiKey: NCILNNGPOXLNPV-MDWZMJQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  131
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS
  申请人：Srivastava Rakesh K.

  公开号：US20080214547A1

  公开（公告）日：2008-09-04

  This invention describes a series of methods and compositions for prevention and treatment of diseases such as cancer. One aspect of the invention describes small molecule-based drugs that can be used to bind to death receptors TRAIL-R1/DR4 and/or TRAIL-R2/DR5 and induce apoptosis in cancer cells, while sparing normal cells. The invention also describes TRAIL Death Receptor Agonists/Activators (DRAs) and their uses, such as the induction of apoptosis through caspase-8 and caspase-3 activation. The present invention also describes the methods of treating cancers, such as breast, prostate, colon, pancreatic, ovarian, lung, and brain cancers, leukemia, lymphoma, multiple myeloma, and mesothelioma, using DRAs either as single-agent treatments, or in combination with other therapies.
• APOPTOSIS-INDUCING MOLECULES AND USES THEREFOR
  申请人：Thomas Merlin C.

  公开号：US20140105898A1

  公开（公告）日：2014-04-17

  This invention relates generally to methods and agents for modulating adiposity-related conditions. More particularly, the present invention relates to the use of TRAIL death receptor agonists, including nucleic acids such as TRAIL polynucleotides, peptides and polypeptides including TRAIL polypeptides, TRAIL DR agonist antigen-binding molecules, TRAIL DR peptide agonists as well as small molecule TRAIL DR agonists in compositions and methods for treating or preventing adiposity-related conditions such as obesity, diabetes mellitus and metabolic syndrome.
• US7915245B2
  申请人：——

  公开号：US7915245B2

  公开（公告）日：2011-03-29
• [EN] METHODS AND COMPOSITIONS OF TRAIL-DEATH RECEPTOR AGONISTS/ACTIVATORS<br/>[FR] PROCÉDÉS ET COMPOSITIONS D'AGONISTES/ACTIVATEURS DU RÉCEPTEUR DE MORT TRAIL
  申请人：UNIV TEXAS

  公开号：WO2008094319A2

  公开（公告）日：2008-08-07

  [EN] This invention describes a series of methods and compositions for prevention and treatment of diseases such as cancer. One aspect of the invention describes small molecule- based drugs that can be used to bind to death receptors TRAIL-R 1/DR4 and/or TRAIL- R2/DR5 and induce apoptosis in cancer cells, while sparing normal cells. The invention also describes TRAIL Death Receptor Agonists/Activators (DRAs) and their uses, such as the induction of apoptosis through caspase-8 and caspase-3 activation. The present invention also describes the methods of treating cancers, such as breast, prostate, colon, pancreatic, ovarian, lung, and brain cancers, leukemia, lymphoma, multiple myeloma, and mesothelioma, using DRAs either as single-agent treatments, or in combination with other therapies.
  [FR] L'invention concerne une série de procédés et de compositions pour prévenir et traiter des maladies telles que le cancer. Un aspect de l'invention décrit des médicaments à base de petites molécules qui peuvent être utilisés pour créer une liaison avec les récepteurs de mort TRAIL-R1/DR4 et/ou TRAIL-R2/DR5, et pour induire une apoptose dans des cellules cancéreuses, tout en épargnant les cellules saines. L'invention concerne également des agonistes/activateurs du récepteur de mort TRAIL (DRA) et leurs utilisations, telles que l'induction d'une apoptose par l'intermédiaire d'une activation de la caspase-8 et de la caspase-3. La présente invention concerne également les procédés de traitement de cancers, tels que le cancer du sein, de la prostate, du côlon, du pancréas, de l'ovaire, du poumon et du cerveau, ainsi que le traitement de la leucémie, du lymphome, du myélome multiple et du mésothéliome, en utilisant des DRA comme traitements par agent unique ou en combinaison avec d'autres thérapies.